Drug intelligence / Profile preview

ACIT-1

Development stage: Phase 2
Lead developer: Cancer Vaccines Limited
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

ACIT-1 is an investigational allogeneic cell immunotherapy, also described as a cancer vaccine, under development by Cancer Vaccines Limited. It is designed as an immunostimulant therapeutic vaccine intended to restore and enhance anti-cancer immune responses in patients with cancer, including pancreatic ductal adenocarcinoma and hematological cancers. The product is formulated as a cell suspension for intradermal injection. Its mechanism of action involves stimulating the immune system to recognize and attack cancer cells[1][2][3].

Other names: allogeneic cell immune therapy 1

Beyond the preview

Go deeper on ACIT-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACIT-1.

Explore the full profile